This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: thrombosis

March 2010 Br J Cardiol 2009;17(Suppl 1):S8-S9

Aspirin – scope and limitations

Paul A Gurbel

Abstract

Identifying targets in the thrombosis pathway Figure 1. Central role of platelets and interaction with coagulation in the genesis of thrombosis (1) Figure 1 summarises the central role of platelets in the genesis of thrombosis.1 The platelet is initially activated in response to shear stress, events such as percutaneous coronary intervention (PCI) or plaque rupture, and the release of local agonists and exposure of the subendothelial components to flowing blood. Tissue factor ‘lights the fire’ by producing minute quantities of thrombin which then amplify the process. Binding of platelets to collagen and von Willebrand

| Full text

March 2010 Br J Cardiol 2009;17(Suppl 1):S3-S4

How do antithrombotics work?

Gordon Lowe

Abstract

Mechanisms Figure 1. Platelet-fibrin thrombus in a coronary artery of a patient with acute coronary syndrome The mechanism of action of aspirin differs from that of other antiplatelet agents. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), completely inhibiting COX-1- dependent synthesis of thromboxane A2 (TXA2), a substance which is a potent vasoconstrictor and promoter of platelet aggregation. Whether low-dose aspirin also exerts a significant anti-inflammatory effect is uncertain: a retrospective sub-analysis suggested that it was more effective in primary prevention in individuals who had high levels of C-reacti

| Full text

March 2010 Br J Cardiol 2009;17(Suppl 1):S5-S7

What is aspirin resistance?

Karsten Schrör

Abstract

(more…)

| Full text

January 2006 Br J Cardiol 2006;13:9-12

The emerging role of vitamin D and its receptor in the pathogenesis of acute coronary syndromes

Khalid Barakat, Graham A Hitman

Abstract

No content available

| Full text

July 2005 Br J Cardiol 2005;12:255-6

What’s in a name? From anticoagulation clinics to thrombosis management centres

David A Fitzmaurice

Abstract

No content available

| Full text

July 2003 Br J Cardiol 2003;10:288-92

COX-2 inhibitors and cardiovascular risk

COX-2 inhibitors and cardiovascular risk Mike Schachter

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now